Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool August 9, 2007 Brian Lawler	BioMarin Gets Busy BioMarin Pharmaceutical has a busy remainder of 2007 ahead of it, including regulatory decisions, six clinical trials, and the potential for new products to enter the pipeline.
The Motley Fool April 1, 2008 Brian Lawler	BioMarin Drug Heads Overseas One of the pharmaceutical's enzyme replacement therapy drugs gets approved in Japan.
The Motley Fool November 8, 2007 Charly Travers	BioMarin Tips Its Hand BioMarin Pharmaceutical awaits an FDA decision on its drug Kuvan for the treatment of phenylketonuria. The company's recent conference call implies approval is imminent.
The Motley Fool October 29, 2009 Brian Orelli	Small and Volatile, but Not for Long BioMarin is growing.
The Motley Fool April 30, 2008 Brian Lawler	BioMarin's Bodacious Earnings BioMarin raises revenue guidance for all of its marketed drugs, thanks to strong sales so far in 2008.
The Motley Fool May 2, 2007 Brian Lawler	BioMarin Moves Ahead The drug developer released first-quarter financial results. Even though BioMarin is not yet profitable, its management team has proven capable in all areas of drug development, from the clinical stage to commercialization. Investors, take note.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool August 6, 2008 Brian Lawler	BioMarin's New Drugs Mostly Hit Their Targets Near-term volatility in a drugmaker's shares can make for long-term opportunities. Such is the current case with BioMarin Pharmaceutical.
The Motley Fool February 19, 2009 Brian Orelli	BioMarin Is Off Track Shares of BioMarin Pharmaceutical, a darling of the drug world whose shares more than doubled in 2007, come crashing down because the growth of years past seems to be waning.
The Motley Fool February 27, 2007 Brian Lawler	Mostly Good From BioMarin Drugmaker BioMarin updates investors on its drug pipeline and quarterly financial results.
The Motley Fool July 31, 2009 Brian Orelli	The Little Orphan That Could After a rough start to the year, Rule Breakers pick BioMarin Pharmaceutical is back on track.
The Motley Fool July 30, 2010 Brian Orelli	A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs.
The Motley Fool May 17, 2005 Charly Travers	BioMarin Bounces Back After a stumble, one biotech firm is returning to the market's good graces. BioMarin stock has shot up 30% in the past two months and is near its 52-week high.
The Motley Fool December 31, 2010 Brian Orelli	2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions.
The Motley Fool November 2, 2006 Brian Lawler	BioMarin's in Good Health This biopharma has a leg up on the competition by getting its finances in order. Even with its small pipeline, BioMarin appears to be running smoothly. Investors, take note.
The Motley Fool October 8, 2007 Charly Travers	Scanning 4 Biotechs There are major events set for the following biotech companies during this quarter. Investors, take note: BioMarin Pharmaceutical... Exelixis... Neurocrine Biosciences... Pain Therapeutics...
The Motley Fool February 28, 2011 Brian Orelli	Rare Diseases, Big Opportunity "Orphan" drugs to keep your eye on.
The Motley Fool May 3, 2007	BioMarin's Big Moves: Fool by Numbers The pharmaceutical released first-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...
The Motley Fool December 31, 2007 Brian Lawler	The Anatomy Of An Approved Drug An independent audit by the FDA provides a useful summary of the characteristics of drugs approved by the agency.
The Motley Fool November 14, 2007 Brian Lawler	Is the FDA Still Approving New Drugs? Lately the FDA seems more reluctant to approve new drugs than it once was. Let's take a look at the actual numbers from the past eight years.
The Motley Fool March 8, 2010 Brian Orelli	Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting.
The Motley Fool March 1, 2005 Charly Travers	From Rags to Riches One biotech's fate reveals the formula for spotting turnaround investments. BioMarin has yet to turn the corner, but that time is quickly approaching.
The Motley Fool September 9, 2010 Brian Orelli	Will These Drugs Get Past the FDA This Month? See what the FDA has on its decision calendar for the rest of September.
The Motley Fool June 3, 2004 Charly Travers	Small Drug Market, Big Hopes BioMarin is going to file for approval in the U.S. and Europe in the fourth quarter of this year after its succesful phase 3 trial of Aryplase. If the drug is approved, it would likely be on the market toward the end of 2005.
The Motley Fool December 7, 2011 Brian Orelli	As the Biotech Saying Goes... Another delay for Protalix BioTherapeutics makes you think.
The Motley Fool May 31, 2011 David Williamson	Roundtable: The World's Best Biotechs Motley Fool analysts choose these as their favorite biotech stocks: Aeterna Zentaris... Seattle Genetics... BioMarin Pharmaceutical... Amarin...
The Motley Fool October 5, 2011 Brian Orelli	1 Sure Sign of an FDA Approval Transcept Pharmaceuticals shoots up 34% after announcing that the FDA had classified its resubmission as a class 1 response.
The Motley Fool September 14, 2010 Luke Timmerman	Arena Obesity Drug Effective by "Slim Margin"; Shares Tumble The market is reacting negatively to news about the company's weight-loss drug.
The Motley Fool January 28, 2011 Brian Orelli	Value Investing, Biotech Style Biotech investors should regard every binary event as a varying degree of confidence in a positive or negative result.
The Motley Fool March 27, 2009 Brian Orelli	Trading Up With the $95 From Genentech Genentech is gone; here's what you should replace it with.
The Motley Fool March 31, 2011 Brian Orelli	Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good.
The Motley Fool October 27, 2009 Brian Orelli	Small Market, Small Acquisition, Still a Good Move BioMarin does everything small.
The Motley Fool August 26, 2010 Travers & Jayson	Will BioMarin Pharmaceutical Burn You? Is BioMarin Pharmaceutical on strong financial footing?
IndustryWeek October 19, 2011	FDA: A Future Innovation Partner? Could the Food and Drug Administration reform itself to help manufacturers create new medical technologies?
The Motley Fool May 5, 2008 Brian Orelli	A Short Wait for Discovery Labs? The company gets a third letter about Surfaxin, but should be able to satisfy the FDA soon.
Pharmaceutical Executive June 1, 2012 Jill Wechsler	Innovation and Collaboration A rash of "pro-innovative" approaches for testing and regulating medical products offer ways to speed more new products to market.
Pharmaceutical Executive March 1, 2012 Ron Cohen	FDA's Necessary Dose of Reality There's no fast-acting salve, but there are several steps that can be taken to streamline many of the procedures at FDA. And it begins with leadership.
The Motley Fool May 1, 2007 Brian Lawler	Cardiome Plays Dealmaker Cardiome signs a deal to develop one of Eli Lilly's drug candidates. Investors, take note.
The Motley Fool January 7, 2009 Brian Orelli	A Free Call Option on a Drug Orphan-drug specialist BioMarin announces that it has licensed Riquent, La Jolla Pharmaceutical's phase 3 lupus nephritis treatment.
The Motley Fool August 6, 2007 Brian Orelli	Congress' Delay May Hurt Drugmakers The reauthorization of the Prescription Drug User Fee Act is delayed. If you're an investor in drug companies, now might be a good time to call your representatives and senators.
The Motley Fool May 20, 2010 Brian Orelli	FDA Transparency! A Big Win for Investors The Food and Drug Administration has possibly just made things easier for investors. Let's just hope drug companies don't shoot it down.
Pharmaceutical Executive February 1, 2011 Jill Wechsler	Challenges, Changes, Commitments The Three Cs could be taxing on FDA resources as the new Congress brings stiffer oversight and leadership revisions to the agency
Pharmaceutical Executive August 1, 2012 Jill Wechsler	Fleshing Out FDASIA Medical apps, e-submissions, counterfeit drugs, and imports tucked into fairly "clean" user-fee renewal legislation. In late June leading legislators reached across party lines to quickly approve the Food and Drug Administration Safety and Innovation Act.
The Motley Fool August 28, 2009 Brian Orelli	Is There Life After a 714% Return? It doesn't get any less risky for Immunomedics.
Pharmaceutical Executive January 1, 2009 Jill Wechsler	FDA Turnaround Time Will more resources and new leadership fix FDA, or is a major overhaul in order?
The Motley Fool December 13, 2010 Brian Orelli	Yep, We Still Want to Lowball You sanofi-aventis still wants investors shares in Genzyme, but it's not willing to step up the price.
The Motley Fool February 26, 2007	BioMarin's Big Quarter: Fool by Numbers The pharmaceutical released fourth-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...
The Motley Fool April 16, 2004 Charly Travers	Genzyme's Minor Disappointment The latest sales figures for Genzyme's newest drug, Aldurazyme, show that a potential growth-driving drug may be stalling out.
The Motley Fool August 16, 2005 Roger Friedman	Adrenaline Stocks With just a small portion of your portfolio, high-growth stocks can supercharge your returns.
Managed Care March 2008 Thomas Morrow	When Diet is Not Enough, a Well Known Metabolic Disorder Can Now be Managed Better Through Medication New drug, Kuvan, can provide benefit to those with Phenylketonuria (PKU), but diet should still be monitored in conjunction with treatment.